FN2 Earnings Intelligence
Royalty Pharma plc income statement (quarterly)
Royalty Pharma plc (RPRX) Income Statement (quarterly) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - |
| - Cash | $1,087.7 | $631.9 | $938.9 | $586.4 | $812 |
| + Debt | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - |
| Revenue | $568.2 | $578.7 | $609.3 | $630.6 | $674.1 |
| % Growth | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| % Margin | - | - | - | - | - |
| EBITDA | - | - | - | $564.2 | - |
| % Margin | - | - | - | 89.5% | - |
| Net Income | $238.3 | $30.2 | $288.2 | $294.7 | $17.9 |
| % Margin | 41.9% | 5.2% | 47.3% | 46.7% | 2.7% |
| Diluted EPS | $0.55 | $0.07 | $0.67 | $0.67 | $0.04 |
| % Growth | - | - | - | - | - |
| Operating Cash Flow | $596.1 | - | - | $718.2 | - |
| CapEx | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Revenue | $568.2 | $578.7 | $609.3 | $630.6 | $674.1 |
| Gross Profit | - | - | - | - | - |
| EBITDA | - | - | - | $564.2 | - |
| Net Income | $238.3 | $30.2 | $288.2 | $294.7 | $17.9 |
| Diluted EPS | $0.55 | $0.07 | $0.67 | $0.67 | $0.04 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $1,087.7 | $631.9 | $938.9 | $586.4 | $812 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | $6,618.8 | $7,003.1 | $8,565.7 | $8,576.4 | $8,581.9 |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | $596.1 | - | - | $718.2 | - |
| Capital Expenditure | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - |
| Gross Margin | - | - | - | - | - |
| EBITDA Margin | - | - | - | 89.5% | - |
| Net Margin | 41.9% | 5.2% | 47.3% | 46.7% | 2.7% |
| FCF Margin | - | - | - | - | - |
| Diluted EPS Growth | - | - | - | - | - |
Get the RPRX recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.